Company News

2024-04-22
The Phase Ib clinical trial of IMM0306 in combination with lenalidomide for relapsed/refractory DLBCL completed the first patient enrollment
On April 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco"), HKEX stock code: 01541.HK) announced that the Phase Ib clinical trial of IMM0306 in combination with len
View more
2024-04-18
Phase III clinical study of Timdarpacept combined with Tirellizumab for refractory cHL approved by CDE
On April 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as " ImmuneOnco "), HKEX stock code: 01541.HK) announced that the Phase III clinical study protocol of Timdarpacept (R&D number: IMM01) combined with Tirellizumab for PD-1/PD-L1 inhibitor failed Classic Hodgkin lymphoma (cHL) was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration.
View more
2024-04-07
Five innovative drug studies of ImmuneOnco were accepted by the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024
On April 7, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) , announced that five innovative drug studies were accepted by the American Society of Clinical Oncology (ASCO) Annual Meeting in 2024
View more
2024-03-11
ImmueOnco’s IMM0306 combined with lenalidomide for the advanced relapsed/refractory follicular lymphoma (FL) completed the phase Ib dose escalation and officially entered phase II clinical trial
On March 11, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that the Phase Ib/II clinical study of the company developed bispecific antibody-receptor recombinant protein drug targeting both CD47 and CD20 (Project No.: IMM0306) in combination with lenalidomide (Study No.: IMM0306-003) for the treatment of advanced relapsed/refractory follicular lymphoma (FL) was discussed at the SRC meeting and the Phase II recommended dose was determined, So the project entered Phase II clinical trial officially. This is another milestone achievement in the rapid development of ImmuneOnco.
View more
2024-02-22
ImmuneOnco will release research data from projects of IMM0306, IMM27M, and IMM5605 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
On February 22, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (referred to as "ImmuneOnco"“the company’, Hong Kong Stock Exchange stock code: 01541.HK) announced that it will present single-agent data of the IMM0306 Phase I and IMM27M Phase I clinical trials and preclinical data of IMM5605 in the form of poster presentations at the 2024 American Association for Cancer Research (AACR 2024) Annual Meeting hold in San Diego, USA, April 5-10.
View more
2024-02-17
ImmuneOnco (01541.HK) included in the Hang Seng Composite Index
On February 17, 2024, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (referred to as "ImmuneOnco", Hong Kong Stock Exchange stock code: 01541.HK) announced that, according to the latest quarterly index series released by Hang Seng Indexes Co., Ltd., ImmuneOnco was included in the Hang Seng Composite Index constituent stocks, which will officially take effect on March 4 (Monday) this year.
View more
Total 56 12345678910
0.086031s